Obesity Research Doctors Association takes the lead in efficient and safe prescription of GLP-1 drugs: Health and Welfare News
【Health and Welfare News】 With the advent of ‘We Gobi’, the dream obesity treatment GLP-1 agent that boasts groundbreaking effects, the perception that ‘obesity is a disease’ is gaining momentum.
As public interest in weight loss increases, interest in obesity treatment will naturally increase, and as a result, it is expected that the movement to approach obesity treatment as ‘disease treatment’ will increase.
In particular, there are concerns about side effects and misuse of Wegobee, but experts believe that it will overcome these and open a new era in obesity treatment.
The Korean Association of Obesity Research (Chairman Min-Jeong Kim, Chairman Cheol-Jin Lee) held its 35th Fall Academic Conference at the Lotte Hotel on the 10th.
This academic conference was a success with over 1,300 attendees, reflecting the interest in obesity treatment, especially with the launch of ‘Wegobi’, which is receiving global attention as a dream obesity treatment, in Korea.
The Obesity Research Medical Association emphasized the need for the obesity treatment ‘We Gobi’ and announced that it would present guidelines to ensure proper use.
Chairman Kim Min-jeong said, “With the launch of the obesity treatment drug ‘WeGobee,’ obesity has never been the focus of national attention as it is now.” He added, “With the domestic launch of WeGoBe, many doctors seem to want to start treating obesity.”
He said, “About 1 billion people around the world suffer from obesity. However, in Korea, there is a misconception that obesity treatment is beauty treatment,” he said. “However, obesity is a disease, and we have prepared a program to help members treat it properly as obesity treatment experts.”
Chairman Kim said, “As an orthodox obesity society for private practitioners, I hope that the Korean Association of Obesity Research Physicians will serve as a good guide to systematically educate people to start obesity treatment and provide efficient and safe prescriptions for GLP-1 agents.” He said.
In particular, “Obesity is a disease that needs to be treated well, but it is often perceived as a cosmetic treatment. The launch of WeGobee provided an opportunity to recognize that obesity is a disease. “We will take this opportunity to do our best to help all citizens overcome obesity by playing a role as an Obesity Research Doctors Association,” he emphasized.
Chairman Lee Cheol-jin continued, “Now is the era of GLP-1 agents. GLP-1 preparations are showing potential for use beyond cosmetics as a treatment for chronic diseases such as cardiovascular disease, arthritis, and kidney disease. “Doctors who treat obesity must become experts on GLP-1 agents,” he emphasized.
Regarding the side effects and misuse of ‘Wegobee’, he said, “It is not long before GLP-1 drugs are used for all diseases in our country,” and “Those who treat obesity should be the best experts in obesity treatment. “In line with the GLP-1 era, the Obesity Research Doctors Association will work harder to research obesity treatment,” he said.
In particular, he emphasized that Wigobi is more effective and has fewer side effects than existing treatments.
He said, “Wegobee is very effective in weight loss. “The most severe side effects are nausea and vomiting, which are no different from existing treatments, and the side effects of pancreatitis, which has recently become an issue, are similar, and it is safer for endocrine cancer,” he emphasized.
In addition, it was repeatedly emphasized that ‘WeGobee’ is safer and more effective than existing treatments, and its effectiveness in preventing other diseases such as dementia, osteoarthritis, snoring, and heart disease is incomparable to the side effects.
Chairman Kim Min-jeong said, “It has now been four weeks since the launch of WeGobee. It has no side effects and is more effective than expected. “In the future, the Obesity Research Medical Association plans to conduct research to see if there will be better results when we focus on disease rather than weight loss for Korean people and share it with our members,” he said.
In addition, the Obesity Research Physicians Association regarding WeGobee’s health insurance coverage diagnosed that it is not cost-effective.
Director Kim Choong-gi said, “Recently, there has been a shift in perception that obesity treatment can become a target for treatment.” He added, “The issue of insurance coverage is a matter of seeing whether it will contribute to universal health. It must be studied in accordance with reality and sufficiently applied while looking at the cost. “There are a lot of things to do,” he argued.
In particular, “In a study targeting patients with cardiovascular disease, it is reported that it reduces cardiac death, myocardial infarction, and stroke by about 20%,” he said. “Wegobi reduces serious diseases and, compared to the effects of existing treatments, it is You can compare. He pointed out, “As far as I know, the reason non-coverage is not available for seriously ill patients is not on scientific grounds, but because it is not cost-effective.”
In relation to this, Chairman Kim Min-jeong said, “In order to apply insurance benefits to obesity treatment drugs, sufficient discussion with experts must be conducted first,” and added, “The Obesity Research Doctors Association, as an orthodox obesity society for private practitioners, systematically provides obesity treatment education and provides effective treatment for GLP-1 drugs in particular.” He emphasized, “It will serve as a proper guide to ensure safe prescriptions.”
Meanwhile, the Obesity Research Physicians Association stated that doctors’ prescribing rights regarding over-prescription of obesity treatment drugs through non-face-to-face treatment should be respected.
Chairman Lee Cheol-jin said, “Opinions are divided about the excessive prescription of Wigobi. However, this is a difference in the prescription standards rather than the non-face-to-face treatment itself,” he said. “Doctors prescribe comprehensively considering the individual patient’s condition, including obesity, and accompanying diseases. Therefore, clinicians’ right to prescribe should be respected,” he emphasized.